| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Andrzej Górski | Q9152165 |
| Krystyna Dabrowska | Q89854851 | ||
| P2093 | author name string | Zuzanna Kaźmierczak | |
| P2860 | cites work | [Phagotherapy in terms of bacteriophage genetics: hopes, perspectives, safety, limitations] | Q53993766 |
| Epidemiology and control of the 'modern' methicillin-resistant Staphylococcus aureus. | Q54432327 | ||
| Comparison of virulence and antibiotic resistance genes of food poisoning outbreak isolates of Staphylococcus aureus with isolates obtained from bovine mastitis milk and pig carcasses. | Q54570545 | ||
| Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. | Q52711083 | ||
| Recurrent ventriculoperitoneal shunt infection caused by small-colony variants of Staphylococcus aureus. | Q53848714 | ||
| The impact of resistance to methicillin in Staphylococcus aureus bacteremia on mortality. | Q53980052 | ||
| Phage Therapy in Clinical Practice: Treatment of Human Infections | Q22061778 | ||
| Bacteriophage biocontrol of plant pathogens: fact or fiction? | Q24170216 | ||
| Bacteriophage therapy | Q24550616 | ||
| The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages | Q24555731 | ||
| Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme | Q24609957 | ||
| Bacteriophage lysins as effective antibacterials | Q24648457 | ||
| Experimental phage therapy against Staphylococcus aureus in mice | Q24685170 | ||
| Methicillin-resistant Staphylococcus aureus among companion and food-chain animals: impact of human contacts | Q26851783 | ||
| Phage cocktails and the future of phage therapy | Q26995797 | ||
| Staphylococcus aureus infections | Q28131787 | ||
| Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections | Q28394377 | ||
| Invasive methicillin-resistant Staphylococcus aureus infections in the United States | Q29616087 | ||
| The two-component cell lysis genes holWMY and lysWMY of the Staphylococcus warneri M phage varphiWMY: cloning, sequencing, expression, and mutational analysis in Escherichia coli | Q30160261 | ||
| Romulus and Remus, two phage isolates representing a distinct clade within the Twortlikevirus genus, display suitable properties for phage therapy applications | Q30585271 | ||
| Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice | Q31793558 | ||
| Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials | Q33237777 | ||
| 5500 Phages examined in the electron microscope | Q33260858 | ||
| The effect of bacteriophages T4 and HAP1 on in vitro melanoma migration. | Q33401067 | ||
| Control of methicillin-resistant Staphylococcus aureus in the hospital setting | Q33646834 | ||
| Comparison of several methods for preserving bacteriophages | Q33695950 | ||
| Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group | Q33852247 | ||
| Endolysins as antimicrobials | Q38022881 | ||
| Efficient designs: factorial randomized trials | Q38027382 | ||
| Bacteriophages show promise as antimicrobial agents | Q38552887 | ||
| Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of Staphylococcus aureus bacteriophage 187. | Q39547308 | ||
| Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives | Q39690702 | ||
| Pros and cons of phage therapy | Q41083979 | ||
| Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model | Q41092030 | ||
| Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential | Q41542875 | ||
| Virulent bacteriophage for efficient biocontrol of Listeria monocytogenes in ready-to-eat foods | Q41854276 | ||
| Phage P68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus | Q41885981 | ||
| Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. | Q42121862 | ||
| Small Colony Variants ofStaphylococcus aureusand Pacemaker-related Infection | Q42588816 | ||
| Sequence analysis of a Staphylococcus aureus gene encoding a peptidoglycan hydrolase activity | Q42614645 | ||
| Methicillin-resistant Staphylococcus aureus nasal carriage among injection drug users: six years later | Q43029228 | ||
| Purification of the Staphylococcus aureus bacteriophages VDX-10 on methacrylate monoliths | Q43147786 | ||
| Efficacy of staphylococcal bacteriophage in the treatment of purulent lung and pleural diseases | Q43479120 | ||
| Staphylococcal bovine mastitis in France: enterotoxins, resistance and the human Geraldine methicillin-resistant Staphylococcus aureus clone | Q43490997 | ||
| The functions of bacteriophage proteins | Q43546873 | ||
| Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase | Q43820230 | ||
| Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms | Q43837288 | ||
| Genetically enhanced cows resist intramammary Staphylococcus aureus infection | Q44213530 | ||
| Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. | Q44323706 | ||
| Emergence of methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of late-onset nosocomial pneumonia in intensive care patients in the USA. | Q44534374 | ||
| Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme | Q44607884 | ||
| Use of bacteriophage and antibiotics for prevention of acute postoperative empyema in chronic suppurative lung diseases | Q44619688 | ||
| Species identification and phylogenetic relationships based on partial HSP60 gene sequences within the genus Staphylococcus | Q45313370 | ||
| Characterization for enterotoxin production, virulence factors, and antibiotic susceptibility of Staphylococcus aureus isolates from various foods in Portugal | Q46096109 | ||
| Lytic activity of the recombinant staphylococcal bacteriophage PhiH5 endolysin active against Staphylococcus aureus in milk | Q46353015 | ||
| Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. | Q46475739 | ||
| Staphylococcus aureus endocarditis: a consequence of medical progress | Q46561771 | ||
| Bacterial strains colonizing subcutaneous catheters of personal insulin pumps. | Q46768792 | ||
| Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. | Q46936223 | ||
| P-27/HP endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections | Q47588177 | ||
| Phage inactivation of foodborne pathogens on cooked and raw meat. | Q50064877 | ||
| Studies on bacteriophage penetration in patients subjected to phage therapy. | Q54768824 | ||
| Unexpected sequence types in livestock associated methicillin-resistant Staphylococcus aureus (MRSA): MRSA ST9 and a single locus variant of ST9 in pig farming in China | Q56771873 | ||
| The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure? | Q57923584 | ||
| Immunogenic effect of bacteriophage in patients subjected to phage therapy | Q68718343 | ||
| [Use of combined phages in suppurative-inflammatory diseases] | Q68786341 | ||
| The preservation of mycobacteriophages by means of freeze drying | Q69753932 | ||
| A study of the microbiological status of Irish farmhouse cheeses with emphasis on selected pathogenic and spoilage micro-organisms | Q72410931 | ||
| An automated method for the detection of staphylococcal heat stable deoxyribonuclease in dairy products | Q73232370 | ||
| Persistent wound infection after herniotomy associated with small-colony variants of Staphylococcus aureus | Q73499911 | ||
| "My enemy's enemy is my friend." Using phages to fight bacteria | Q76386512 | ||
| Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin | Q79281958 | ||
| [Clinical evaluation after an introduction of our manual for antibiotic use during perioperative period and a notification policy of use of the antibiotics for MRSA] | Q80174969 | ||
| The distribution of enterotoxin and enterotoxin-like genes in Staphylococcus aureus strains isolated from nasal carriers and food samples | Q80234238 | ||
| Inhibition of bacteriophage K proliferation on Staphylococcus aureus in raw bovine milk | Q81082423 | ||
| Identification, cloning, and initial characterization of rot, a locus encoding a regulator of virulence factor expression in Staphylococcus aureus | Q33994152 | ||
| Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. | Q34005533 | ||
| Phage therapy experience at the Eliava Institute | Q34013252 | ||
| Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats | Q34123647 | ||
| Antibacterials as adjuncts to incision and drainage for adults with purulent methicillin-resistant Staphylococcus aureus (MRSA) skin infections | Q34153675 | ||
| Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. | Q34179620 | ||
| Phage treatment of human infections. | Q34254407 | ||
| Staphylococcus epidermidis biofilms: importance and implications. | Q34303524 | ||
| Implication of milk and milk products in food-borne diseases in France and in different industrialised countries | Q34324686 | ||
| The two-component lysis system of Staphylococcus aureus bacteriophage Twort: a large TTG-start holin and an associated amidase endolysin | Q34471853 | ||
| LysGH15, a Novel Bacteriophage Lysin, Protects a Murine Bacteremia Model Efficiently against Lethal Methicillin-Resistant Staphylococcus aureus Infection | Q34487554 | ||
| Bacteriophage endolysins as a novel class of antibacterial agents. | Q34505697 | ||
| Bacteriophage therapy: an alternative to conventional antibiotics. | Q34549532 | ||
| Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. | Q34737900 | ||
| Bacteriophage therapy for the treatment of infections. | Q34995297 | ||
| Staphylococcus aureus and food poisoning | Q35199279 | ||
| Phage therapy: a reappraisal of bacteriophages as antibiotics. | Q35212109 | ||
| Bacterial viruses against viruses pathogenic for man? | Q36104105 | ||
| Bacteriophage endolysins--current state of research and applications | Q36175326 | ||
| Hand-washing and methicillin-resistant Staphylococcus aureus | Q36238032 | ||
| Carriage ofStaphylococcus aureusin random samples of a normal population | Q36251861 | ||
| Hematogenous vertebral osteomyelitis due to Staphylococcus aureus in the adult: clinical features and therapeutic outcomes | Q36283242 | ||
| Antimicrobial drug resistance of Staphylococcus aureus in dairy products | Q36719389 | ||
| Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides | Q37048735 | ||
| Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia | Q37064359 | ||
| Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues | Q37355394 | ||
| Preventing biofilms of clinically relevant organisms using bacteriophage | Q37375379 | ||
| Methicillin-resistant Staphylococcus aureus in extended-care facilities: experiences in a Veterans' Affairs nursing home and a review of the literature | Q37649273 | ||
| Staphylococcus aureus as an infectious agent: overview of biochemistry and molecular genetics of its pathogenicity | Q37655031 | ||
| Pathologic fractures in children with acute Staphylococcus aureus osteomyelitis | Q37973237 | ||
| Molecular mechanisms of Staphylococcus aureus nasopharyngeal colonization. | Q37974379 | ||
| Methicillin-resistant Staphylococcus aureus (MRSA) infections among HIV-infected persons in the era of highly active antiretroviral therapy: a review of the literature | Q37978658 | ||
| Clinical aspects of phage therapy. | Q38022878 | ||
| Genomics of staphylococcal Twort-like phages--potential therapeutics of the post-antibiotic era. | Q38022880 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P921 | main subject | virus | Q808 |
| Staphylococcus aureus | Q188121 | ||
| antibiotic resistance | Q380775 | ||
| bacteria | Q10876 | ||
| complementary therapy | Q64831118 | ||
| P304 | page(s) | 2551-2570 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool | |
| P478 | volume | 6 |
| Q90192502 | A Kayvirus Distant Homolog of Staphylococcal Virulence Determinants and VISA Biomarker Is a Phage Lytic Enzyme |
| Q37717103 | A Novel Staphylococcus Podophage Encodes a Unique Lysin with Unusual Modular Design |
| Q40867366 | Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework |
| Q46152057 | Bacteriophage treatment of intransigent diabetic toe ulcers: a case series |
| Q64899610 | Bacteriophages engineered to display foreign peptides may become short-circulating phages. |
| Q40041460 | Characterization of vB_SauM-fRuSau02, a Twort-Like Bacteriophage Isolated from a Therapeutic Phage Cocktail |
| Q33815301 | Complete Genome Sequence of Staphylococcus aureus Bacteriophage pSa-3. |
| Q39019401 | Delivering phage therapy per os: benefits and barriers |
| Q92858069 | Effect of serum anti-phage activity on colibacillosis control by repeated phage therapy in broilers |
| Q58591012 | Effects of Bacteriophage K on Expression of Cytokines and Activation Markers by Human Dendritic Cells In Vitro |
| Q40856467 | Genomic analysis of Staphylococcus phage Stau2 isolated from medical specimen. |
| Q50100609 | Guidelines to Compose an Ideal Bacteriophage Cocktail |
| Q90473947 | Nonconventional Therapeutics against Staphylococcus aureus |
| Q92468490 | Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review |
| Q64933125 | Photolysis of Staphyloxanthin in Methicillin-Resistant Staphylococcus aureus Potentiates Killing by Reactive Oxygen Species. |
| Q91043238 | Preventive effect of the phage VB-SavM-JYL01 on rabbit necrotizing pneumonia caused by Staphylococcus aureus |
| Q48477478 | Re-establishing a place for phage therapy in western medicine |
| Q41989580 | Refractory Pseudomonas Bacteremia in a 2-Year-Old Sterilized by Bacteriophage Therapy. |
| Q40051003 | Strategies for editing virulent staphylococcal phages using CRISPR-Cas10. |
| Q64896953 | Synergistic antimicrobial activity of bacteriophages and antibiotics against Staphylococcus aureus. |
| Q61813277 | The Ability of Lytic Staphylococcal Podovirus vB_SauP_phiAGO1.3 to Coexist in Equilibrium With Its Host Facilitates the Selection of Host Mutants of Attenuated Virulence but Does Not Preclude the Phage Antistaphylococcal Activity in a Nematode Infect |
| Q57283588 | The disparate effects of bacteriophages on antibiotic-resistant bacteria |
| Q88494546 | Transient Sulfenic Acids in the Synthesis of Biologically Relevant Products |
Search more.